Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
06990 科倫博泰生物-B
Listing Date2023/07/11
Listing Price60.600
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    2 lot
  • One Lot Success Rate

Sichuan Kelun-Biotech Biopharmaceutical Co. is a biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in oncology, immunology and other therapeutic areas in China and globally.


As of 20 Jun 2023, the Group strategically advance a differentiated and clinically valuable pipeline of 33 assets, including 14 in clinical stage, five in pivotal trial- or NDA registration-stage, nine in phase 1- or phase 2-stage, and nine out-license agreements.


The Group has two ADC drugs as its Core Products, namely, SKB264 and A166. SKB264 is a novel phase 3-stage TROP2 ADC positioned as a late-line monotherapy and part of early-line combination therapies for treating various advanced solid tumors, including breast cancer (BC), non-small cell lung cancer (NSCLC) and other major cancers. A166 is a differentiated NDA registration-stage HER2 ADC positioned as a late-line monotherapy to treat advanced HER2 solid tumors.


The Group also owned 79 issued patents in China, 22 issued patents in the U.S., 52 issued patents in other jurisdictions, and 255 pending patent applications.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot100
No. of Offer Shares22.45M H shares
No. of International Offer Shares20.20M H shares
No. of HK Offer Shares2.24M H shares
Offer Price$60.60 - $72.80
Stock Code6990
Sponsor(s)Goldman Sachs (Asia) L.L.C., CITIC Securities (Hong Kong) Limited
Underwriter(s)Goldman Sachs (Asia) L.L.C., CLSA Limited, Citigroup Global Markets Asia Limited, ICBC International Securities Limited, BOCOM International Securities Limited
Application PeriodJun 29 (Thu) - noon, Jul 04 (Tue)
Price Determination DateJul 04 (Tue)
Result Announcement DateOn or before Jul 10 (Mon)
Result Announcement DateOn or before Jul 10 (Mon)
Result Announcement DateOn or before Jul 10 (Mon)
Dealings in Shares commence onJul 11, 2023. (Tue)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$60.60 - $72.80
Capitalization13.08B - 15.71B
NAV / share ($)$-11.82 - $-9.93 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 66.70, the net proceeds raised would be HKD 1.38B, of which
45% : Research, development and commercialization of Core Products, namely, SKB264 and A166
30% : Research, development and commercialization of other key products, including A140, A167, A400 and A223
12% : Fund the continued development of technology platforms for ADCs, biologics and small molecules
8% : Expansion of manufacturing capabilities and quality control system
5% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.